About The Study: In this study of 6,866 individuals with COVID-19, nirmatrelvir and ritonavir (Paxlovid [Pfizer]) treatment was associated with reduced risk of COVID-19 hospitalization or death in clinically extremely vulnerable individuals, with the greatest benefit observed in severely immunocompromised individuals. No reduction in the primary outcome (death from any cause or emergency hospitalization with COVID-19 within 28 days) was observed in lower-risk individuals, including those age 70 or older without serious comorbidities.
Authors: Colin R. Dormuth, Sc.D., of the University of British Columbia in Vancouver, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2023.36678)
